Advertisement

Laboratory role in prostate cancer diagnosis and management: a case report

  • Andrea Mariano
  • Angelo Salzo
  • Giovanni Francario
  • Franca Di Fonte
  • Antonietta Perrella
  • Marilù Magri
Caso clinico

Summary

This case report describes the clinical course of a prostate cancer case, from the first diagnosis until the exitus in four years and it wants to highlight the relevance of the Laboratory in managing this disease. This case report suggests that data provided by the laboratory can help the clinicians during the diagnostic and therapeutic course, allowing a robust disease monitoring and follow-up, compared to radiological or nuclear medicine diagnostic reports.

Keywords

Prostate Prostate cancer Prostate specific antigen (PSA) Treatment Monitoring Follow-up 

Ruolo del laboratorio nella diagnosi e gestione del cancro alla prostata: un caso clinico

Notes

Acknowledgements

To my grandfather Andrea, for his support and trust during my way in the medical profession.

To Diana Isabel Fanelli, for helping in the linguistic review.

Conflict of interest

None.

Studies carried out on human being and animals

All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from the patient’s family (legal guardian) for publication of this case report and accompanying data.

Authors’ contribution

Andrea Mariano as corresponding author contributed to literature search, to get and prepare figures, data collection and interpretation, and writing the report; all other authors contributed equally to the drafting of the article.

References

  1. 1.
    Bostwick DG, Eble JN (2008) Urological Surgical Pathology, 2nd edn. Mosby-Year Book Publisher, St. Louis, Missuori, USA Google Scholar
  2. 2.
    Welch HG, Schwartz LA, Woloshin S (2011) Overdiagnosed: Making People Sick in the Pursuit of Health. Beacon Press, Boston, Massachusetts, USA Google Scholar
  3. 3.
    Miller DC, Hafez KS, Stewart A et al. (2003) Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 98:1169–1178 CrossRefPubMedGoogle Scholar
  4. 4.
    Catalona WJ, Richie JP, Ahmann FR et al. (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151:1283–1290 CrossRefPubMedGoogle Scholar
  5. 5.
    Catalona WJ (2018) Prostate cancer screening. Med Clin North Am 102:199–214 CrossRefPubMedGoogle Scholar
  6. 6.
    Velonas VM, Woo HH, dos Remedios CG et al. (2013) Current status of biomarkers for prostate cancer. Int J Mol Sci 14:11034–11060 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fascelli M, Rais-Bahrami S, Sankineni S et al. (2016) Combined biparametric prostate magnetic resonance imaging and prostate-specific antigen in the detection of prostate cancer: a validation study in a biopsy-naive patient population. Urology 88:125–134 CrossRefPubMedGoogle Scholar
  8. 8.
    Luzurier A, Jouve De Guibert PH, Allera A et al. (2018) Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. J Magn Reson Imaging.  https://doi.org/10.1002/jmri.25991 PubMedCrossRefGoogle Scholar
  9. 9.
    Petersen LJ, Strandberg J, Stenholt L et al (2018) Reporting and handling of indeterminate bone scan results in the staging of prostate cancer: a systematic review. Diagnostics (Basel) 8:pii E9.  https://doi.org/10.3390/diagnostics8010009
  10. 10.
    Hoffmann MA, Miederer M, Wieler HJ et al. (2017) Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT. Oncotarget 8:111073–111083 PubMedPubMedCentralGoogle Scholar
  11. 11.
    Lopci E, Saita A, Lazzeri M et al. (2018) 68Ga-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI: a prospective observational study. J Urol 200:95–103 CrossRefPubMedGoogle Scholar
  12. 12.
    Faiena I, Kim S, Farber N et al. (2017) Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers. Oncotarget 8:109783–109790 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Claps M, Petrelli F, Caffo O et al. (2018) Testosterone levels and prostate cancer prognosis: systematic review and meta-analysis. Clin Genitourin Cancer 16:165–175 CrossRefPubMedGoogle Scholar
  14. 14.
    Merseburger AS, Alcaraz A, von Klot CA (2016) Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther 29:7263–7274 CrossRefGoogle Scholar
  15. 15.
    Arija JA, Beca RG, López CL et al. (2012) Treatment of the patient with castration-resistant biochemical progression of prostate cancer. Arch Esp Urol 65:185–192 PubMedGoogle Scholar
  16. 16.
    Wu JT, Erickson AJ, Tsao KC et al. (2000) Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 30:175–178 PubMedGoogle Scholar
  17. 17.
    Niedworok C, Tschirdewahn S, Reis H et al. (2017) Serum chromogranin A as a complementary marker for the prediction of prostate cancer-specific survival. Pathol Oncol Res 23:643–650 CrossRefPubMedGoogle Scholar
  18. 18.
    Fan L, Wang Y, Chi C et al. (2017) Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. BJU Int 120:226–232 CrossRefPubMedGoogle Scholar
  19. 19.
    Grodsky MB, Sidani SM (2015) Radiation proctopathy. Clin Colon Rectal Surg 28:103–111 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kishan AU, Kupelian PA (2015) Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects. Brachytherapy 14:148–159 CrossRefPubMedGoogle Scholar
  21. 21.
    Moulton CR, House MJ, Lye V et al. (2016) Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol 11:144 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Figueiredo JC, Grau MV, Haile RW et al. (2009) Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 101:432–435 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tomaszewski JJ, Richman EL, Sadetsky N et al. (2014) Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE™. J Urol 191:971–976 CrossRefPubMedGoogle Scholar
  24. 24.
    Stratton J, Godwin M (2011) The effect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract 28:243–252 CrossRefPubMedGoogle Scholar
  25. 25.
    Price AJ, Travis RC, Appleby PN et al. (2016) Circulating folate and vitamin B12 and risk of prostate cancer: a collaborative analysis of individual participant data from six cohorts including 6875 cases and 8104 controls. Eur Urol 70:941–951 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mosli HH, Dennis A, Kocha W et al. (2012) Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 97:E1731–E1735 CrossRefPubMedGoogle Scholar
  27. 27.
    Ohlmann CH, Jäschke M, Jaehnig P et al. (2017) Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. Trials 18:457 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Thakur A, Roy A, Ghosh A et al. (2018) Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother 101:211–218 CrossRefPubMedGoogle Scholar

Copyright information

© Società Italiana di Patologia Clinica e Medicina di Laboratorio 2018

Authors and Affiliations

  1. 1.Dipartimento di Medicina e Scienze della Salute “V. Tiberio”Università degli Studi del MoliseCampobassoItalia
  2. 2.UOC di UrologiaPresidio Ospedaliero “A. Cardarelli”CampobassoItalia
  3. 3.UOC di Medicina di LaboratorioPresidio Ospedaliero “A. Cardarelli”CampobassoItalia

Personalised recommendations